Efficacy of 308-nm Excimer Laser for Primary Localized Cutaneous Amyloidosis Treatment in Asians

NCT03068156 — Not applicable, Completed, 15 participants, Chulalongkorn University

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Efficacy of 308-nm Excimer Laser for Primary Localized Cutaneous Amyloidosis Treatment in Asians: Pilot Study

Registry	NCT03068156
Status	Completed
Phase	Not applicable
Study type	Interventional; non randomized, parallel, masking: single, treatment
Enrollment	15 (Actual)
Sponsor	Chulalongkorn University (Other); collaborators: Ratchadapiseksompotch Fund
Conditions	Lichen Amyloidosis
Interventions	308-nm excimer laser (Radiation)
Dates	start 2022-01-31, primary completion 2023-01-30, completion 2023-03-02, first posted 2017-03-01, last updated 2026-05-13
Locations	1 site in Thailand

-Summary

Efficacy of 308-nm excimer laser for primary localized cutaneous amyloidosis treatment in Asians, pilot study.

Expand all sections · Collapse all

+Arms and interventions

Arm	Type	Interventions	Description
excimer laser	Experimental	Radiation: 308-nm excimer laser
Control	No intervention

308-nm excimer laser (Radiation): monochromator UVB laser (308nm)

+Outcome measures

Primary outcomes

Roughness evaluation by using Visioscan® VC98 [Change from baseline roughness at every 2 weeks up to 16 weeks]: The improvement of roughness evaluation

+Eligibility

Sex: All, ages: 18 Years to any, accepts healthy volunteers

Inclusion Criteria:

* Patients, aged >18 years old with lichen amyloidosis diagnosed by using clinical presentation and pathologic features

Exclusion Criteria:

* Those with cutaneous amyloidosis associated systemic diseases
* Pregnancy or lactating woman
* Those who are allergic to urea, olive oil
* Those who are photosensitive to ultraviolet radiation
* Those who had been previously treated with medications/ radiation/ laser within 3 months for systemic and 1 month for topical therapy

+Locations (1)

Facility	City	Country	Status
King Chulalongkorn Memorial Hospital	Bangkok, Bangkok	Thailand

+Investigators

Einapak Amnarttrakul, M.D., Principal investigator, Chulalongkorn University